A Comparative Study of the Effect of Carbamazepine and Valproic Acid on the Pharmacokinetics and Metabolic Profile of Topiramate at Steady State in Patients with Epilepsy

Summary:  Purpose: To compare the influence of enzyme‐inducing comedication and valproic acid (VPA) on topiramate (TPM) pharmacokinetics and metabolism at steady state.

[1]  René H Levy,et al.  Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine , 2005, Epilepsia.

[2]  Kiyoshi Yamaoka,et al.  Statistical moments in pharmacokinetics , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  E. Perucca,et al.  Topiramate Pharmacokinetics in Children and Adults with Epilepsy , 2005, Clinical pharmacokinetics.

[4]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[5]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[6]  Y. Blanco,et al.  Topiramate Serum Concentration-to-Dose Ratio: Influence of Age and Concomitant Antiepileptic Drugs and Monitoring Implications , 2004, Therapeutic drug monitoring.

[7]  R. Twyman,et al.  Pharmacokinetic Interactions of Topiramate , 2004, Clinical pharmacokinetics.

[8]  E. Perucca,et al.  Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response , 2003, Therapeutic drug monitoring.

[9]  M. Brodie,et al.  Topiramate and Lamotrigine Pharmacokinetics during Repetitive Monotherapy and Combination Therapy in Epilepsy Patients , 2003, Epilepsia.

[10]  E. Perucca,et al.  Analysis of Topiramate and Its Metabolites in Plasma and Urine of Healthy Subjects and Patients With Epilepsy by Use of a Novel Liquid Chromatography–Mass Spectrometry Assay , 2003, Therapeutic drug monitoring.

[11]  Graeme J. Sills,et al.  P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice , 2002, Epilepsy & Behavior.

[12]  M. Bialer,et al.  Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients , 2002, Epilepsia.

[13]  M. Contin,et al.  Topiramate Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Antiepileptic Drugs , 2002, Therapeutic drug monitoring.

[14]  T. May,et al.  Serum Concentrations of Topiramate in Patients With Epilepsy: Influence of Dose, Age, and Comedication , 2002, Therapeutic drug monitoring.

[15]  S. Johannessen.  Seventh Eilat Conference on New Antiepileptic Drugs (Eilat VII) , 2002, Seizure.

[16]  Wu Wn,et al.  Recent advances in biotransformation of CNS and cardiovascular agents. , 2000 .

[17]  W. Wu,et al.  Recent advances in biotransformation of CNS and cardiovascular agents. , 2000, Current drug metabolism.

[18]  R. Davis,et al.  Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. , 1997, Drugs.

[19]  S. Nortey,et al.  Synthesis of hydroxylated derivatives of topiramate, a novel antiepileptic drug based on D-fructose: investigation of oxidative metabolites. , 1997, Carbohydrate research.

[20]  W. Rosenfeld,et al.  Comparison of the Steady‐State Pharmacokinetics of Topiramate and Valproate in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1997, Epilepsia.

[21]  R. Nayak,et al.  Steady‐State Pharmacokinetics of Topiramate and Carbamazepine in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1996, Epilepsia.

[22]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages , 1996, Neurology.

[23]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages , 1996, Neurology.

[24]  R. Shank,et al.  Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. , 1987, Journal of medicinal chemistry.